Company: ZVRA
Filing Date: 2025-03-31
Form Type: PREC14A
Source: 0001193125-25-068746
Chunk: 58

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: PREC14A
Chunk 58
---
 |     |                   $700,000 |     |                   $700,000 |     |                   $735,000 |
| Adrian Quartel, M.D., FFPM   |     |                        N/A |     |                   $485,000 |     |                   $500,000 |
| R. LaDuane Clifton, MBA, CPA |     |                   $446,000 |     |                   $463,800 |     |                   $480,000 |

Cash-BasedIncentive Compensation Our NEOs generally have the opportunity to earn annual performance bonuses based on the achievement of short-term performance goals. The NEOs’ 2024 target annual cash bonuses, expressed as a percentage of base salary, were: 60% for Mr. McFarlane and 40% for the other two NEOs. Our Compensation Committee generally determines annual bonuses for our NEOs by multiplying (a) base salary, by (b) target cash bonus percentage, by (c) the level of achievement of corporate and/or individual performance objectives (if applicable). Up to an additional 40% of each individual’s target bonus may be earned for outperformance based on certain bonus enhancements, as described below. In addition, the Compensation Committee retains discretion to adjust annual bonuses as it determines appropriate to reflect Company performance, individual performance or other factors that the Compensation Committee believes to be appropriate. The annual performance bonuses for 2024 were weighted 100% on corporate objectives. Corporate goals were categorized into four key areas, with weighting and objectives as follows:

| • |     | 20% Financial: Balance sheet metrics, consisting of target cash balances; |

56

| • |     | 30% Commercial: Net product revenue, market access, and conversion of U.S. Expanded Access Program participants; |

| • |     | 30% Pipeline: Product approval and advancement of other clinical candidates; and |

| • |     | 20% Corporate: Strategic plan, expansion of investor relations activities and talent management. |

Additionally, the Company offers bonus enhancements of up to an additional 40% tied to exceeding market capitalization growth and other performance targets. For 2024, the Board determined that the corporate objectives were achieved at 129.5% of target. Specifically, the financial targets were achieved at 75% of target (weighted total of 15.0%), the commercial targets were achieved at 89% of target (weighted total of 26.6%), the pipeline targets were achieved at 100% of target (weighted total